During the coronavirus disease 2019 (COVID-19) pandemic, patients are more likely to have delayed cancer screenings rather than their doctors and clinics.
Nearly 24% of patients with cancer delayed screenings because of the coronavirus disease 2019 (COVID-19) pandemic, according to a recently released American Society of Clinical Oncology (ASCO) survey of 1142 individuals with current or past cancer diagnoses. The survey included 4012 individuals overall, including caregivers and family members.
Among those who delayed screenings, the patient made the decision to cancel or delay a screening two-thirds of the time; 63% of patients who delayed or skipped screenings reported being concerned about these delays, ASCO said.
The survey addressed not only COVID-19 issues but also perceptions of how an individual’s race affects access to the best quality cancer care. ASCO said 59% of those surveyed agreed racism affects the quality of care an individual receives in the US health care system, 53% said Black Americans are less likely to have access to the same quality of cancer care as White Americans, and 19% said race affects a person’s likelihood of surviving cancer.
Non-White respondents were more likely to agree that race affects quality of care in the United States (Black, 76%; Hispanic, 70%; Asian, 66%; White, 53%), and Black adults are more likely than White adults to have not been scheduled for any cancer screening appointments during the COVID-19 pandemic (68% vs 61%).
Clinical Trial Perceptions
The survey findings indicated 75% of respondents would be willing to participate in a clinical trial for cancer treatment if they had cancer; however, just 53% said they are knowledgeable about clinical trials, and 48% said they believe patients with cancer who participate in clinical trials do not receive the best possible care and “are just part of an experiment.”
Among patients with cancer who have limited their contact with others to avoid contracting COVID-19, 84% were White and 73% were Black. The survey said 49% of patients with cancer have made “a lot of sacrifices” in their daily living because of their higher risk for contracting COVID-19, with more Blacks indicating so than Whites (61% vs 47%).
Many also indicated they have not had enough emotional support (33%) or help (22%), such as for picking up medications, during the pandemic.
ASCO said two-thirds of family members and caregivers would like to do more to support their loved ones with cancer in both practical and emotional ways.
The types of effects on cancer care caused by the pandemic reported by those with current or past cancer included delayed visits (16%), doctor consultations made via telehealth instead of in person (15%), cancer monitoring tests delayed (12%), health coverage lost (2%), treatment such as surgery or radiation cancelled (2%), and treatment regimens changed (1%). ASCO said 68% reported no effects on cancer care as a result of COVID-19.
Click here for results of the 2019 ASCO survey.
Top 5 Most-Read Oncology Articles of 2024
December 24th 2024The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.